Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, July 26, 2017 ) Primary biliary cirrhosis is a chronic disease of the liver that slowly destroys the bile ducts within the liver. Symptoms include fatigue itchy skin dry eyes jaundice swollen feet and ankles pain in the upper right portion of the abdomen and diarrhea. Predisposing factors include age and history of infections. Treatment includes bile acid sequestrants and liver transplantation. Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Primary Biliary Cirrhosis-Pipeline Review H2 2017 provides comprehensive information on the therapeutics under development for Primary Biliary Cirrhosis (Gastrointestinal) complete with analysis by stage of development drug target mechanism of action (MoA) route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics its complete research and development history and latest news and press releases.
The Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Biliary Cirrhosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes the molecules developed by Companies in Phase III Phase II Phase I Phase 0 and Preclinical stages are 1 11 5 1 and 1 respectively.
Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/primary-biliary-cirrhosis-pipeline-review-h2-2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Biliary Cirrhosis (Gastrointestinal) . - The pipeline guide reviews pipeline therapeutics for Primary Biliary Cirrhosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description descriptive licensing and collaboration details R&D brief MoA & other developmental activities. - The pipeline guide reviews key companies involved in Primary Biliary Cirrhosis (Gastrointestinal) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Primary Biliary Cirrhosis (Gastrointestinal) therapeutics based on mechanism of action (MoA) drug target route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Primary Biliary Cirrhosis (Gastrointestinal)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001881452/sample
Reasons to buy
- Procure strategically important competitor information analysis and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Primary Biliary Cirrhosis (Gastrointestinal) . - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Primary Biliary Cirrhosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles AbbVie Inc Amarantus Bioscience Holdings Inc Astellas Pharma Inc AstraZeneca Plc Bristol-Myers Squibb Company Coronis NeuroSciences Ltd Eli Lilly and Company F. Hoffmann-La Roche Ltd H. Lundbeck A/S Heptares Therapeutics Ltd Intra-Cellular Therapies Inc Iproteos SL Luc Therapeutics Inc Neuralstem Inc
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001881452/discount
List of Tables Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS) H2 2017 Number of Products under Development by Companies H2 2017 Number of Products under Development by Companies H2 2017 (Contd..1) H2 2017 Products under Development by Companies H2 2017 Products under Development by Companies H2 2017 (Contd..1) H2 2017 Number of Products by Stage and Target H2 2017 Number of Products by Stage and Mechanism of Action H2 2017 Number of Products by Stage and Route of Administration H2 2017 Number of Products by Stage and Molecule Type H2 2017 Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by AbbVie Inc H2 2017 Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Amarantus Bioscience Holdings Inc H2 2017 Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Astellas Pharma Inc H2 2017 Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by AstraZeneca Plc H2 2017 Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Bristol-Myers Squibb Company H2 2017 Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Coronis NeuroSciences Ltd H2 2017 Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Eli Lilly and Company H2 2017 Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by F. Hoffmann-La Roche Ltd H2 2017 Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by H. Lundbeck A/S H2 2017 Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Heptares Therapeutics Ltd H2 2017 Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Intra-Cellular Therapies Inc H2 2017 Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Iproteos SL H2 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001881452/buy/2000
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
Source: EmailWire.com
|
|
|
|